Medical device giant Philips was well aware of a dangerous defect in millions of its once-popular breathing machines, and should not blame the testing lab that helped identify the potential risks to patients, an Erie testing lab argued in a filing in federal court on Friday.
PSN Labs, which is being sued by Philips, said in a 48-page rebuttal that its test results were not what prompted a massive recall in 2021 of the company’s CPAPs and ventilators.
“Philips, similar to its attempts against other third-parties, is attempting to deflect attention to PSN Labs and away from Philips’ own failures, negligence, concealment, and recklessness,” the filing states in federal court in Pittsburgh.
The lab’s response comes just weeks after Philips filed a lawsuit against the lab, alleging the lab made errors in testing that led the global device maker to launch a more severe recall than it otherwise would have.
The global company pulled the machines off the shelves after tests found that the foam used to keep them quiet could break down into particles and release dangerous chemicals into the masks of patients.
CEO Roy Jakobs signaled in a podcast appearance last month that the company is ready to move on from the fallout, but the global company’s legal fight could take months or longer to play out.
Read More
Philips has already agreed to pay more than $1 billion to settle hundreds of personal injury claims and has signed a consent decree with the Food and Drug Administration that mandates greater safety monitoring and bans the company from selling the devices in the U.S. until certain conditions are met.
However, a criminal investigation by the Department of Justice’s consumer protection branch and the FBI continues, as well as a civil case with SoClean, which made an ozone cleaner that people used with Philips machines.
In its filing, PSN denied claims that its test results were faulty and pointed to findings from Philips’ own scientists, other testing labs and an external expert that found critical problems with the foam in Philips’ machines — a material known to break down under heat and moisture and release chemicals into the air paths of the devices.
Philips “covered up its mistakes by masking, skewing, and cherry-picking favorable test results in efforts to minimize and hide from the public and regulatory bodies significant risks that had long been known,” the lab’s filing states.
By the time Philips contracted PSN in 2019, it had already begun to suspect that the foam placed inside its breathing machines to keep them quiet could break down over time, potentially putting users at risk, according to PSN.
“Philips already knew a recall was necessary,” the filing states, but asked PSN to identify specific chemicals in the foam that could put users at risk.
Philips then began asking PSN for the raw data behind its testing, which the lab said raised “numerous red flags.” PSN said employees inside Philips warned the lab that the request for raw data was “Philips’ attempt to change the compounds to more favorable results.” An accreditor warned them not to turn the data over.
In a separate ruling on PSN’s testing data filed earlier this summer, U.S. District Judge Joy Flowers Conti stipulated that “in any disclosure of the testing data, Philips shall not disparage PSN.”
In response to PSN’s filing, Philips Respironics restated its claims from its lawsuit.
“Philips Respironics has conducted significant independent testing on the foam in its sleep therapy devices and we are confident that there is no appreciable harm to health in patients,” the company said.
“This lawsuit is about holding PSN accountable for its unacceptable conduct. Philips Respironics would have pursued a different and more focused recall had PSN not made its serious mistakes and greatly overestimated the potential risk to patients, prompting unjustified concern.”
Although Philips has said a significant number of tests since the recall show the foam does not cause long-term harm and has walked back its earlier warnings, the FDA has rejected the company’s claims, saying the material is capable of causing serious injuries and death.
The FDA continues to classify the recall as a Class 1, which is reserved for medical devices that are capable of causing the greatest harm.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.